15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies

Page 13 of 14

2. United Therapeutics Corporation (NASDAQ:UTHR)

Renaissance Technologies Q4 Stake: $737.2 million

Number of Hedge Fund Holders: 42

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and manufactures organ replacements and treatments for organ disorders. The company’s three primary medications, Tyvaso, Orenitram, and Remodulin, are targeted at patients, hospitals, and specialty pharmacies.

TD Cowen reiterated its Buy rating for United Therapeutics Corporation (NASDAQ:UTHR) on May 7, citing a stable $400 price target. The endorsement follows a recent meeting with the company’s management, which took place after their earnings call for the first quarter. TD Cowen analysts stated that management discussed the ongoing introduction of Tyvaso PH-ILD and expressed confidence in the drug’s ability to treat Idiopathic Pulmonary Fibrosis (IPF), with preliminary results anticipated in the second half of the year.

United Therapeutics Corporation (NASDAQ:UTHR) exceeded market expectations with its first quarter 2025 financial performance. The company reported earnings per share of $6.63, surpassing the projected $6.53, and achieved record revenue of $794.4 million, significantly higher than the expected $728.34 million. Strong demand across its treprostinil product lines, including Tyvaso and Remodulin, contributed to a 17% year-over-year increase in revenue.

Page 13 of 14